1153. Safety and Potential Efficacy of Exosomes Overexpressing CD24 (EXO-CD24) for the Prevention of Clinical Deterioration in Patients with Moderate or Severe COVID-19: A Phase II, Randomized, Single-blinded Study

MLA

Ioannis Grigoropoulos, et al. “1153. Safety and Potential Efficacy of Exosomes Overexpressing CD24 (EXO-CD24) for the Prevention of Clinical Deterioration in Patients with Moderate or Severe COVID-19: A Phase II, Randomized, Single-Blinded Study.” Open Forum Infectious Diseases, vol. 9, Dec. 2022. EBSCOhost, https://doi.org/10.1093/ofid/ofac492.991.

APA

Ioannis Grigoropoulos, Georgios Tsioulos, Artemis Kastrissianakis, Shiran Shapira, Nadir Arber, Garyfallia Poulakou, Konstantinos Syrigos, Vasiliki Rapti, Ioannis Xynogalas, Konstantinos Leontis, Vasileios Ntousopoulos, Vissaria Sakka, Mina Gaga, Zafeiris Sardelis, Andreas Fotiadis, Lamprini Vlassi, Chrysoula Kontogianni, Anastasia Levounets, Maria Tsakona, … Sotirios Tsiodras. (2022). 1153. Safety and Potential Efficacy of Exosomes Overexpressing CD24 (EXO-CD24) for the Prevention of Clinical Deterioration in Patients with Moderate or Severe COVID-19: A Phase II, Randomized, Single-blinded Study. Open Forum Infectious Diseases, 9. https://doi.org/10.1093/ofid/ofac492.991

Chicago

Ioannis Grigoropoulos, Georgios Tsioulos, Artemis Kastrissianakis, Shiran Shapira, Nadir Arber, Garyfallia Poulakou, Konstantinos Syrigos, et al. 2022. “1153. Safety and Potential Efficacy of Exosomes Overexpressing CD24 (EXO-CD24) for the Prevention of Clinical Deterioration in Patients with Moderate or Severe COVID-19: A Phase II, Randomized, Single-Blinded Study.” Open Forum Infectious Diseases 9 (December). doi:10.1093/ofid/ofac492.991.